Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes

Archives of Internal Medicine

Volumn 160, Issue 4, 2000, Pages 501-509

  Chatzinikolaou, Ioannis ^a,b   Abi Said, Dima ^b   Bodey, Gerald P ^a   Rolston, Kenneth V I ^a   Tarrand, Jeffrey J ^b   Samonis, George ^b,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; IMIPENEM; PENICILLIN DERIVATIVE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; BLOOD CULTURE; CHILD; DRUG EFFICACY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUTROPHIL; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SHOCK;

EID: 0034723745     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.4.501     Document Type: Article

References (55)

1. Schimpff SC. Gram-negative bacteremia. Support Care Cancer. 1993;1:5-18.
2. Forkner CE Jr, Frei El, Edgcomb JH, et al. Pseudomonas septicemia: observations on 23 cases. Am J Med. 1958;25:877-889.
3. Curtin JA, Petersdorf RG, Bennet IL. Pseudomonas bacteremia: review of ninety-one cases. Ann Intern Med. 1961;54:1077-1107.
4. McCabe WR, Jackson GG. Gram-negative bacteremia: etiology and ecology. Arch Intern Med. 1962;110:847-855.
5. Hersh EM, Bodey GP, Nies BA, Freireich EJ. Causes of death in acute leukemia: a ten year study of 414 patients from 1954-1963. JAMA. 1965;193:105-109.
6. Whitecar JP Jr, Luna M, Bodey GP. Pseudomonas bacteremia in patients with malignant diseases. Am J Med Sci. 1970;60:216-223.
7. Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med. 1984;144: 1845-1851.
8. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med. 1985;145:1621-1629.
9. Donowitz GR, Mandell GL. β-lactam antibiotics (1). N Engl J Med. 1988;318: 419-426.
10. Eliopoulos GM, Eliopoulos CT. Activity in vitro of the quinolones. In: Hopper DC, Wolfson JS, eds. Quinolone Antimicrobial Agents. 2nd ed. Washington, DC: American Society for Microbiology; 1993:161-194.
11. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch Intern Med. 1996;156:2121-2126.
12. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis. 1998;17:701-708.
13. Ehni WF, Reller LB, Ellison RTD. Bacteremia in granulocytopenic patients in a tertiary-care general hospital. Rev Infect Dis. 1991;13:613-619.
14. Arpi M, Victor MA, Moller JK, et al. Changing etiology of bacteremia in patients with hematological malignancies in Denmark. Scand J Infect Dis. 1994;26:157-162.
15. Johansson PJ, Sternby E, Ursing B. Septicemia in granulocytopenic patients: a shift in bacterial etiology. Scand J Infect Dis. 1992;24:357-360.
16. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis. 1996;15:291-296.
17. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997;112:235-243.
18. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
19. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493-496.
20. Schimpft SC, Greene WH, Young VM, Wiernik PH. Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. J Infect Dis. 1974; 130(suppl):S24-S31.
21. Tapper ML, Armstrong D. Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. J Infect Dis. 1974;130(suppl):S14-S23.
22. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323-1332.
23. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever: Infectious Diseases Society of America. Clin Infect Dis. 1997;25:551-573.
24. Rolston KV, Elting L, Waguespack S, Ho DH, LeBlanc B, Bodey GP. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Chemotherapy. 1996;42:348-353.
25. Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH. Susceptibility surveillance among gram-negative bacilli at a cancer center. Chemotherapy. 1999; 45:325-334.
26. Ucar E, Karanes C, Abella S, Chandrasekar PH. Trends in bacteremia among cancer/ marrow transplant patients during 1991-1995. In: Program and abstracts of the Tenth International Symposium on Infections in the Immunocompromised Host; June 21-24. 1998; Davos, Switzerland. Abstract 11.
27. Smolianskaya A, Dmitrieva N, Sokolova E, Khvatova, Kulaga E. Etiology of infectious complications in cancer patients. In: Program and abstracts of the Tenth International Symposium on Infections in the Immunocompromised Host; June 21-24, 1998; Davos, Switzerland. Abstract 14.
28. Persson L, Vikerfors T, Tidefelt U. Retrospective study of 274 episodes of bacteremia in acute non-lymphocytic leukemia during two periods, 1980-1986 and 1990-1996. In: Program and abstracts of the Tenth International Symposium on Infections in the Immunocompromised Host; June 21-24, 1998; Davos, Switzerland. Abstract 26.
29. Favero MS, Carson LA, Bond WW, Petersen NJ. Pseudomonas aeruginosa: growth in distilled water from hospitals. Science. 1971;173:836-838.
30. Kominos SD, Copeland CE, Grosiak B, Postic B. Introduction of Pseudomonas aeruginosa into hospital via vegetables. Appl Microbiol Biotechnol. 1972;24:567-570.
31. Samish Z, Etinger-Tulczynska R. Distribution of bacteria within the tissue of healthy tomatoes. Appl Microbiol Biotechnol. 1963;11:7-10.
32. Kaminishi H, Hamatake H, Cho T, et al. Activation of blood clotting factors by microbial proteinases. FEMS Microbiol Lett. 1994;121:327-332.
33. Teplitz C. Pathogenesis of Pseudomonas vasculitis and septic lesions. Arch Pathol Lab Med. 1965;80:297-307.
34. Dorff GJ, Geimer NF, Rosenthal DR, Rytel MW. Pseudomonas septicemia: illustrated evolution of its skin lesion. Arch Intern Med. 1971;128:591-595.
35. Rajan RK. Spontaneous bacterial peritonitis with ecthyma gangrenosum due to Escherichia coli. J Clin Gastroenterol. 1982;4:145-148.
36. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25:247-259.
37. Bisbe J, Gatell JM, Puig J, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis. 1988;10:629-635.
38. Mallolas J, Gatell JM, Miro JM, et al. Analysis of prognostic factors in 274 consecutive episodes of Pseudomonas aeruginosa bacteremia. Antibiot Chemother. 1991;44:106-114.
39. Tillotson JR, Lerner AM. Characteristics of nonbacteremic Pseudomonas pneumonia. Ann Intern Med. 1968;68:295-307.
40. Pennington JE, Reynolds HY, Carbone PP. Pseudomonas pneumonia: a retrospective study of 36 cases. Am J Med. 1973;55:155-160.
41. Walsh TJ, Schimpff SC. Antibiotic combinations for the empiric treatment of the febrile neutropenic patient. Schweiz Med Wochensch Suppl. 1983;14:58-63.
42. Korvick JA, Yu VL. Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991;35:2167-2172.
43. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986;315:552-558.
44. Wade JC, Johnson DE, Bustamante CI. Monotherapy for empiric treatment of fever in granulocytopenic cancer patients. Am J Med. 1986;80:85-95.
45. Liang R, Yung R, Chiu E, et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother. 1990; 34:1336-1341.
46. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial: the Intercontinental Antimicrobial Study Group. Ann Intern Med. 1994;120:834-844.
47. Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984;26:870-875.
48. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87:540-546.
49. De Jongh CA, Joshi JH, Newman KA, et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med. 1986; 80:96-100.
50. Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med. 1992;152:283-291.
51. Bodey GP, Whitecar JP Jr, Middleman E, Rodriguez V. Carbenicillin therapy for Pseudomonas infections. JAMA. 1971;218:62-66.
52. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061-1065.
53. Nichols L, Maki DG. The emergence of resistance to β-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution? Chemioterapia. 1985;4:102-109.
54. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A. 1997;94:12106-12111.
55. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol Infect Dis. 1987;6:234-244.